Duopharma Biotech gets premium valuation on vaccine development


Its rating is now a buy with a new discounted cashflow-derived target price of RM4 from RM3.30, which is at a 2% yield.

PETALING JAYA: Duopharma Biotech Bhd has been upgraded to a buy from a sell by RHB Research, given the increased clarity on its chances to participate in vaccine rolloutss in the country.

The research house also noted that its human insulin contract had also been extended.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Trading ideas: SD Guthrie, Dayang, Datasonic, Elridge, Genetec, MN, Bina Puri, Bintai Kinden, MCE, BHIC, Carimin, Tuju Setia, Khee San
Wall St slips as uncertainty surrounds U.S. election
Oil jumps nearly 3% after Opec+ delays output hike, US election in focus
Datasonic acquires 51% stake in ICT firm
High real estate credit growth raises concern
Elridge Energy inks 15-year biomass fuel deal
Bumi Armada’s North Sea contract win to lift earnings
US election may impact US$89bil worth of exports
China stimulus questions to persist long after meeting
Stonepeak nears deal for aircraft lessor ATSG

Others Also Read